A recent large-scale study has highlighted alarming findings regarding the weight-loss drug Wegovy, revealing that users are nearly five times more likely to experience sudden vision loss than those taking its diabetes counterpart, Ozempic. This research, published in the British Journal of Ophthalmology, raises significant public health concerns about the safety profile of semaglutide, the active ingredient in both medications.
Understanding the Findings
The analysis focused on reports submitted to the US Food and Drug Administration (FDA) between December 2017 and December 2024, examining the adverse effects associated with various formulations of semaglutide. Researchers determined that individuals prescribed Wegovy for obesity management exhibited a markedly higher incidence of non-arteritic anterior ischemic optic neuropathy (Naion)—a condition often referred to as an “eye stroke.” This condition leads to a sudden and typically irreversible loss of vision due to inadequate blood flow to the optic nerve.
The study indicated that men face a threefold greater risk of developing Naion compared to women. Although the occurrences of this condition are relatively rare—affecting approximately one in 10,000 individuals on semaglutide—the potential for severe side effects raises crucial questions regarding patient safety and drug administration protocols.
Differences in Drug Formulation
Wegovy, Ozempic, and Rybelsus, all manufactured by Novo Nordisk, contain varying dosages of semaglutide. The distinct formulations and methods of administration may contribute to differing side effect profiles. The analysis suggested that the higher doses and faster-acting nature of Wegovy injections might explain the increased association with vision loss. Conversely, the oral formulation of Rybelsus demonstrated no notable risk, which researchers attributed to its slower absorption rate.
Dr Edward Margolin, an ophthalmologist from the University of Toronto and lead author of the study, emphasised that Naion should be regarded as a legitimate side effect of semaglutide, particularly in the context of rapid weight loss. He cautioned that this could increase the likelihood of developing the condition.
Regulatory Responses and Safety Measures
In light of these findings, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a safety alert in February, advising healthcare professionals and patients to remain vigilant about the symptoms of Naion when prescribing semaglutide. Dr Alison Cave, chief safety officer at the MHRA, reinforced that while the risk remains low, it is essential for both patients and prescribers to be informed about potential side effects.
A spokesperson for Novo Nordisk reiterated the company’s commitment to patient safety, affirming that they actively engage with regulatory authorities to monitor the safety of their products. Although the company acknowledged updates to patient information leaflets regarding Naion, they maintained that the overall benefit-risk assessment for semaglutide remains favourable.
Ongoing Debate and Future Implications
Samantha Mann, a consultant ophthalmologist and diabetic eye screening lead at the Royal College of Ophthalmologists, pointed out that the study’s reliance on reported side effects means it cannot definitively establish causation or the true prevalence of Naion in clinical settings. She noted that her own practice at St Thomas’ Hospital in London has not seen a significant uptick in cases of optic nerve “stroke,” suggesting that further research is needed to clarify the extent of the risk.
Why it Matters
The implications of these findings are profound, highlighting the need for continued scrutiny of weight-loss medications and their potential side effects. As the popularity of drugs like Wegovy and Ozempic grows, so too does the responsibility of healthcare providers to ensure patients are fully informed of the risks involved. With the potential for serious visual impairment linked to these treatments, it is crucial that both patients and healthcare professionals exercise caution and remain alert to the signs of adverse effects. This study serves as a reminder of the delicate balance between achieving health benefits and safeguarding patient safety.
